Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of “Moderate Buy” from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been given a consensus rating of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $12.00.

Several equities analysts have commented on AMRX shares. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 22,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares of the company’s stock, valued at $95,984.30. This trade represents a 67.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Nikita Shah sold 114,492 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the sale, the executive vice president owned 152,743 shares in the company, valued at $1,475,497.38. The trade was a 42.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 609,206 shares of company stock worth $5,700,625. 26.56% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Amneal Pharmaceuticals by 5,975.0% in the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company’s stock valued at $26,000 after purchasing an additional 3,107 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at $31,000. Amalgamated Bank raised its holdings in shares of Amneal Pharmaceuticals by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company’s stock valued at $46,000 after purchasing an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. raised its holdings in shares of Amneal Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company’s stock valued at $66,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Amneal Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company’s stock valued at $98,000 after purchasing an additional 1,735 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $9.97 on Friday. The stock has a market capitalization of $3.13 billion, a P/E ratio of 998.00 and a beta of 1.18. The company has a 50 day moving average price of $9.58 and a 200 day moving average price of $8.37. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $10.68.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Monday, July 21st. The company reported $0.21 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. The firm had revenue of $695.42 million during the quarter. Amneal Pharmaceuticals has set its Q2 2025 guidance at EPS. Research analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.